Repare Therapeutics Inc.

NasdaqGS RPTX

Repare Therapeutics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 42,093,293

Repare Therapeutics Inc. Shares (Diluted, Weighted) is 42,093,293 for the year ending December 31, 2023, a 0.41% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Repare Therapeutics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 41,922,042, a 10.85% change year over year.
Repare Therapeutics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 37,818,115, a 2.48% change year over year.
Repare Therapeutics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 36,902,924, a 0.64% change year over year.
Repare Therapeutics Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 36,668,085, a 132.21% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqGS: RPTX

Repare Therapeutics Inc.

CEO	Mr. Lloyd Mitchell Segal
IPO Date	June 19, 2020
Location	Canada
Headquarters	7210 Frederick-Banting
Employees	179
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

Key trends

Past 5 years